Is Arlington Asset Investment Corp. (AAIC) a Buy, Sell, or Hold?
NYSE : AAIC
Arlington Asset Investment Corp.
$4.84 USD
$0.07 (1.47%)
- Volume
- 341.11K
- Average Volume
- 162.55K
- Market Capitalization
- $137.08M
- P/E Ratio
- 53.78
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.84
- Year Low
- $2.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.51
- Current Ratio
- $0.66
Company Overview
NYSE
J. Rock Tonkel Jr., CPA
REIT - Mortgage
Real Estate
AAIC
9
US
USD
Liquidity Metrics
1.18
0.66
2.08
0.06
0.51
Sales & Valuation
$30.53M
4.49
0.64
-99.70
-0.05
Profitability
$0.09
$5.43M
17.77%
31.26%
2.46%
0.54%
P/E Metrics
53.78
-0.43
-0.43
Analyst Price Target & Rating
0/5
9 Analysts
%
Financial Health Scores
-1.85
6/9
$8.9M
$867.26M
$86.71M
$32.33M
Key Metrics (TTM)
$362.99M
11.89
10.92
0.66
2.46%
3.08%
3.90%
-1.00%
$5.67
-41860 days
Company Executives
| Name | Title |
|---|---|
| J. Rock Tonkel Jr. | President, Chief Executive Officer & Director |
| Claire F. Newman | Managing Director of Institutional Sales Administration |
| D. Scott Parish | Senior Vice President, Chief Administrative Officer & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Arlington Asset Investment Corp. (NYSE:AAIC) Stock
Arlington Asset Investment Corp. (NYSE: AAIC) functions as a real estate investment trust (REIT), primarily channeling its capital into mortgage-backed instruments and various other assets. The company's principal office is located in the Washington, D.C. metropolitan area. For additional information, please refer to www.arlingtonasset.com. ...
2026-07-15 07:30:00
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-AβO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.
2026-07-15 03:30:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop.
2026-07-14 12:00:00
More than 75% of LeqembiÂ-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEAD
2026-07-14 12:00:00
LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a
2026-07-14 11:39:00
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype.
2026-07-14 11:15:00
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd.
2026-07-14 10:00:00
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
2026-07-13 08:49:22
Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer's Association International Conference in London. Wall Street weighed in on the stock last week.
Frequently Asked Questions
-
What is the current Arlington Asset Investment Corp. (AAIC) stock price?
-
Arlington Asset Investment Corp.(NYSE:AAIC) stock price is $4.84 in the last trading session. During the trading session, AAIC stock reached the peak price of $4.84 while $2.53 was the lowest point it dropped to. The percentage change in AAIC stock occurred in the recent session was 1.47% while the dollar amount for the price change in AAIC stock was $0.07.
-
AAIC's industry and sector of operation?
-
The NYSE listed AAIC is part of REIT - Mortgage industry that operates in the broader Real Estate sector.
-
Who are the executives of AAIC?
-
J. Rock Tonkel Jr. | President, Chief Executive Officer & Director
Claire F. Newman | Managing Director of Institutional Sales Administration
D. Scott Parish | Senior Vice President, Chief Administrative Officer & Corporate Secretary
|
| -
How many employees does AAIC have?
-
Number of AAIC employees currently stands at 9. AAIC operates from Potomac Tower, Arlington, VA 22209, US.
-
Link for AAIC official website?
-
Official Website of AAIC is: https://www.arlingtonasset.com
-
How do I contact AAIC?
-
AAIC could be contacted at phone #703-373-0200 and can also be accessed through its website. AAIC operates from Potomac Tower, Arlington, VA 22209, US.
-
How many shares of AAIC are traded daily?
-
The average number of AAIC shares traded daily for last 3 months was 162.55K.
-
What is the market cap of AAIC currently?
-
The market value of AAIC currently stands at $137.08M with its latest stock price at $4.84